Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,190,207 papers from all fields of science
Search
Sign In
Create Free Account
CEV regimen
Known as:
Cytoxan-Etoposide-Vincristine Regimen
, VEC regimen
A regimen consisting of cyclophosphamide, etoposide and vincristine used for the treatment of extensive-stage small cell lung cancer.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
9 relations
Broader (4)
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Etoposide
cisplatin/cyclophosphamide/etoposide protocol
Cyclophosphamide
Paraplatin
Small cell carcinoma of lung
Vincristine
Narrower (1)
VEJ regimen
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.
T. Seremet
,
Simon Planken
,
+7 authors
B. Neyns
Melanoma research
2019
Corpus ID: 52270331
Monoclonal antibodies that block the programmed death-1 (anti-PD-1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) immune…
Expand
2018
2018
Phase II trial of pexa-vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC).
Seong-Geun Kim
,
H. Ha
,
+6 authors
J. Burke
2018
Corpus ID: 80370781
671Background: Pexa-Vec is a vaccinia virus engineered to express granulocyte-macrophage colony stimulating factor (GM-CSF…
Expand
Review
2018
Review
2018
Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma
E. Burke
,
J. Zager
Expert Opinion on Drug Metabolism & Toxicology
2018
Corpus ID: 4023200
ABSTRACT Introduction: Current treatment of advanced melanoma is rapidly changing with the introduction of new and effective…
Expand
Review
2017
Review
2017
Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.
Takeshi Yamada
,
Yukako Hamano
,
+5 authors
M. Abei
Current Cancer Drug Targets
2017
Corpus ID: 3346460
Advanced liver cancers and biliary cancers represent diseases with dismal prognosis because of frequent local invasion and…
Expand
Review
2016
Review
2016
The Role of Intralesional Therapies in Melanoma.
S. Agarwala
Oncology
2016
Corpus ID: 39924510
The US Food and Drug Administration has been rapidly approving new checkpoint inhibitors and targeted therapies for melanoma and…
Expand
2014
2014
New frontier in liver cancer treatment: Oncolytic viral therapy
S. Vilarinho
,
T. Taddei
Hepatology
2014
Corpus ID: 19550608
Oncolytic viruses and active immunotherapeutics have complementary mechanisms of action (MOA) that are both self amplifying in…
Expand
2014
2014
ESTIMATION OF VECTOR ERROR CORRECTION MODEL WITH GARCH ERRORS: MONTE CARLO SIMULATION AND APPLICATIONS
K. Setiawan
,
K. Maekawa
2014
Corpus ID: 43997484
The standard vector error correction (VEC) model assumes the iid normal distribution of disturbance term in the model. This paper…
Expand
2013
2013
Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced…
J. Heo
,
Y. Chao
,
+12 authors
D. Kirn
2013
Corpus ID: 59120487
TPS4161^ Background: Pexa-Vec is a targeted oncolytic and immunotherapeutic vaccinia virus engineered to express human…
Expand
Review
2012
Review
2012
An Examination of Measures Related to Children’s Exposure to Violence for Use by Both Practitioners and Researchers
J. Acosta
,
D. Barnes-Proby
,
+4 authors
D. Schultz
Trauma, Violence, & Abuse
2012
Corpus ID: 206737743
Millions of children each year are exposed to violence in their homes, schools, and communities as both witnesses and victims. As…
Expand
1983
1983
Comparative sequence and structure of different isolates of citrus exocortis viroid.
J. Visvader
,
R. Symons
Virology
1983
Corpus ID: 7897720
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required